Diagnostics
results in more women being referred with low risk of high-grade CIN to colposcopy.
l In general, colposcopy performs poorly when there is a low prevalence of high-grade CIN.
l ZedScan increases the detection of high- grade CIN across multiple centres and different healthcare settings.
l The study confirms the value of a real time adjunctive technology.
Sameer Kothari, CEO at Zilico (the manufacturer of ZedScan) said: “TheEuropean Journal of Obstetrics & Gynecology and Reproductive Biology findings are fantastic news for patients in the UK and further afield. They show how ZedScan helps across different clinical settings in nine countries. Colposcopy has historically relied on a cytology-based screening programme but now, with a DNA/RNA based programme, it requires advanced technology to perform well.1 Zilico’s bioimpedance technology is used at the point of examination during colposcopy and helps patients, clinicians and hospitals. “Not only is this technology meaningful for the patient’s comfort and reassurance, it is quite simply detecting more problems accurately, and in greater detail, allowing people to access the treatment that they really need more efficiently. This is important research that can be shared in the UK and across Europe. Moreover, there is huge potential for the rest of the world and developing economies where cervical cancer goes readily undetected.”
How ZedScan works With colposcopy, clinicians look for cervical intra-epithelial neoplasia (CIN). CIN means a change to the cells in the cervix – this can be high- or low-grade. Cervical cancer is a treatable disease if detected at CIN stage, which is why it’s so important to use technology (such as
ZedScan gives us the ability to confidently rule out disease in many cases and removes the need for a diagnostic biopsy and unnecessary follow-up appointments. This gives our patients peace of mind and helps us to see more patients more quickly by releasing appointment capacity for other patients. Ms Sharon Griffin, Medway NHS Foundation Trust
ZedScan) to detect these changes as early as possible. The adjunct diagnostic device uses EIS (Electrical Impedance Spectroscopy) technology to identify cell changes and provide information on tissue impedance (the rate at which tissue reacts to electrical signals) that cannot always be seen with standard colposcopy. EIS works by measuring seven key cell
parameters at 14 different frequencies: ZedScan differentiates between normal, low-grade and high-grade abnormalities (4-6). Using a single- use EIS sensor, ZedScan takes up to 12 readings from around the cervical transformation zone
following the application of acetic acid. The readings are processed by an in-built algorithm to quantify the degree of abnormality at each reading site, with the results displayed immediately to support clinical decision making. This non-visual, bio-electric technique is used alongside the clinician’s visualisation of the cervix and is proven to detect more high-grade disease, particularly in women with low-grade referrals, which are the most challenging visually. The high sensitivity of the ZedScan device also gives clinicians the confidence to discharge women to surveillance or routine screening when no high-grade disease is indicated, supporting better management of patients from beginning to end. The technology is seeing increasing adoption
across the NHS. Two key value propositions that the NHS look for are provided with ZedScan in routine use across hospital Trusts: improved health economics and better patient outcomes. The improved health economics benefit both the payer and service provider, making ZedScan particularly valuable in the current NHS financial climate. Medway NHS Foundation Trust is the most recent hospital to adopt the technology. Its lead clinician for the colposcopy unit, consultant obstetrician and gynaecologist, Ms Sharon Griffin, said: “ZedScan gives us the ability to confidently rule out disease in many cases and removes the need for a diagnostic biopsy and unnecessary follow-up appointments. This
58
www.clinicalservicesjournal.com I August 2023
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64
